Enterprise Sleep Health Potential Cost Savings
An interactive model of the annual cost of untreated sleep issues across your workforce, and the net savings recoverable through a tiered intervention programme.
01
Workforce inputs
Override defaults with your own screening data
Total headcount · employees
% of workforce
ISI syndrome level (15+)
% of workforce
FIRST > 23 OR mild insomnia (ISI 8–14) · union
02
Context & benchmark
Data provenance
Benchmark cohort
- Somnus Sleep Wellness enterprise screening benchmark — self-administered clinical screening
- N = 118 · 85 Female / 33 Male · mean age 36.1 (SD 6.9)
- 2026 · anonymized aggregate cohort
Singapore context
- Chronic insomnia affects 10–15% of Singaporean adults
- Moderate–severe OSA affects ~30% of the population
Global economic anchor
- Insufficient sleep costs the US economy USD 411B / year (RAND Europe 2017)
- Australian economy lost AUD 66.3B in 2016–17 (Deloitte)
03
The burden at a glance
Click any figure for breakdown
i.Employees at clinical risk
--
--
See breakdown
ii.Annual cost without action
S$0
Syndrome + mild insomnia excess (Daley 2009) + OSA drain (Frost & Sullivan 2016) + 12% progression risk on reactivity-only pool · click for breakdown
See breakdown
iii.Recoverable with intervention
S$0
Move the slider below to
model your programme reach
model your programme reach
See breakdown
Workforce insomnia signal
64%
of the screened cohort showed insomnia symptoms (ISI 8+). 36% showed above-average sleep reactivity (FIRST > 23), and 29% had measurable alertness lapses on the objective PVT.
Sleep debt across your workforce
0 hrs / week
0 full-time equivalents lost to a 0.6 hr weekday deficit (benchmark cohort: 7.2 hr weekday vs 7.8 hr desired; weekend 8.5 hr — social-jetlag signal).
Well-being cost
14%
of household income is what an affected employee would trade to eliminate their insomnia — the intangible quality-of-life cost, separate from productivity loss. RAND Europe 2023, 16-country OECD meta-study.
Employees at clinical risk — breakdown
Annual cost without action — breakdown
Recoverable with intervention — breakdown by tier
04
Programme reach
Model the scenario
How many employees does your programme reach? Set reach independently for each tier to model ROI.
20%
0 of 0 syndrome-insomnia employees reached
Syndrome insomnia · ISI 15+ · CBT-I tier
0%25%50%75%100%
5%
0 of 0 employees reached
Entire company · Slumbr tier
0%25%50%75%100%
05
Intervention tiers
Toggle programmes on / off
Regression insight — predictors of insomnia severity
Lower SHI Sleep Quality is the strongest independent predictor of higher ISI, followed by higher sleep reactivity (FIRST). Employees with both signals are the priority candidates for the Slumbr tier before insomnia crystallises.
— Somnus enterprise screening benchmark, 2026 (anonymized cohort, N=118)
CBT-I (Cognitive Behavioural Therapy for Insomnia) · syndrome cases
0 employees
- Moderate–severe insomnia
- 60–80% improvement rate
- Gold standard first-line treatment
Annual Saving: S$0
Group · 0 treated
Cost breakdown
CompanyS$0
EmployeeS$0
TotalS$0
Individual · 0 treated
Cost breakdown
CompanyS$0
EmployeeS$0
TotalS$0
Slumbr platform · company-wide prevention tier
0 employees
- Open to the entire workforce
- 45-min weekly class
- Prevents symptom→syndrome progression
Annual Saving: S$0
Platform fee — all-in PEPY
Annual Slumbr investment
S$0
S$0 per employee / year · whole workforce
Includes 6 Slumbr instructor certifications at no extra cost · the company runs its own classes
Somnus-delivered classes (when needed)
S$375 per class delivered by Somnus, when needed
06
Projected outcomes
Annual net saving & return on investment
Net annual saving
S$0
Gross saving minus company investment · per year
Annual return on investment
--
Net annual saving ÷ annual company investment
Annual amount recovered
S$0
Gross annual saving from intervention, before costs
Annual company investment
S$0
Toggle programmes above to show investment breakdown
Annual unaddressed cost
S$0
Annual burden still unrecovered
Annual absent days recovered
0
Per year · 4.0 sick days per treated syndrome employee (Daley 2009). RAND 2023 estimates 11–18 absent days/yr for chronic insomnia — this model uses the more conservative figure.
Annual productivity days recovered
0
Per year · 24.8 performance days per treated syndrome employee (Daley 2009). RAND 2023 estimates 44–54 total productivity days/yr for chronic insomnia — this model uses the more conservative figure.
Slide the reach slider to model your scenario
07
Programme framework
Four layers · the two interventions sit within this system
01 · Population engagement
Slumbr classes, workshops and sleep literacy at scale — reduces behavioural obstacles and teaches arousal / stress management. Active in this model.
02 · Targeted pathways
CBT-I and escalation routes for higher-risk employees identified through screening — gold-standard treatment for syndrome-level insomnia. Active in this model.
03 · Digital & screening infrastructure
Included in the Slumbr platform fee — annual Somnus Sleep Health Screening for all employees (repeat screening, trend tracking) and the Slumbr app: on-demand sleep education, guided relaxation & wind-down practices, habit tracking and behavioural nudges. A scalable digital layer that reinforces class content between sessions, bundled with class delivery into a single per-employee licence.
04 · Engagement & adoption
Communications, scheduling, reminders, social proof — decision-architecture that turns intention into sustained participation.
Policy backing — independent evidence
“Workplace interventions are needed to better identify insomnia and mitigate its impacts… Employees, as part of an overall wellness package, should receive evidence-based resources for managing insomnia, such as access to CBT-I.”
— RAND Europe, 2023. The societal and economic burden of insomnia in adults, Policy Recommendation 2
Syndrome tier · CBT-I
Cognitive Behavioural Therapy for Insomnia
Gold standard, first-line treatment for insomnia disorder. 60–80% improvement rate with durable outcomes — improvements persist after treatment ends, unlike medication. A 2024 meta-analysis confirms CBT-I as the most cost-effective insomnia treatment available. For the 900 syndrome-level employees in your workforce, it directly reverses the conditioning and hyperarousal that lock insomnia in place.
Pricing
Group
CompanyS$950
EmployeeS$100
TotalS$1,050
Individual
CompanyS$950
EmployeeS$1,600
TotalS$2,550*
* Average cost per employee
ROI above reflects the S$950 company portion (Group mode). Toggle Group/Individual in the tier card to switch.
Symptom & prevention tier · Slumbr
Slumbr platform — screening + app + 45-minute class
The Slumbr platform bundles three components into one per-employee licence. The Slumbr class is a 45-minute programme of relaxation and mindfulness practices, stress management tools, and goal-setting exercises across 5 modular sessions. It is wrapped together with the Somnus Sleep Health Screening (annual, trend tracking) and the Slumbr app (on-demand education, guided wind-down, habit tracking).
Platform fee: a flat S$12 per-employee-per-year covering the Somnus Sleep Health Screening, the Slumbr app and the Slumbr class licence, with 6 instructor certifications included at no extra cost — charged company-wide and independent of programme reach. The licence lets the company run its own classes. When needed, Somnus can also deliver a class at S$375 per class.
Platform fee: a flat S$12 per-employee-per-year covering the Somnus Sleep Health Screening, the Slumbr app and the Slumbr class licence, with 6 instructor certifications included at no extra cost — charged company-wide and independent of programme reach. The licence lets the company run its own classes. When needed, Somnus can also deliver a class at S$375 per class.
Pricing
Platform fee · flat PEPY, all-in
Platform (per employee / yr)S$12
Instructor certifications (incl.)6
Somnus class, when neededS$375
Class deliveryOwn instructors
What's in the S$12 fee
Somnus Sleep Health Screening✓
Slumbr app✓
Slumbr class licence (run your own)✓
6 instructor certifications✓
Somnus class delivery (optional)S$375/class
Platform investment = whole workforce × S$12 PEPY, flat regardless of programme reach; the reach slider scales clinical savings only. The S$12 fee already includes the Slumbr class licence and 6 instructor certifications (no separate charge), so the company runs its own classes. When needed, Somnus can deliver a class at S$375 per class.
Measurement · Somnus Sleep Health Screening
Sleep Health Screening — white paper deliverable
A white paper is provided at the start and end of the year — an analysis of employees' sleep health and provision of a white paper with recommendations, so the programme's impact can be measured across the year.
- Aggregated report with anonymised data from the Sleep Health Screening among participants on the status of their sleep health
- Including prevalence of insomnia risk, perceived stress and sleep reactivity, obstructive sleep apnea and other sleeping disorders
- Recommendations based on the findings
08
SHI — cohort distribution
N=118 · Somnus enterprise benchmark
Grade distribution · 42.4% good / 53.4% moderate / 4.2% poor
11%
A · 90–100
31.4%
B · 80–89
32.2%
C · 70–79
21.2%
D · 60–69
4.2%
F · <60
Hover a grade to view the clinical description
The C and D bands (53%) are the primary programme population — performance dips and rising risk, but not yet clinical. The D band alone (21%) is a notable signal of widespread moderate-poor sleep that benefits from early, light-touch intervention.
09
Supporting evidence
Click to expand
Cost basis: Daley et al. (2009) — per-person annual cost by sleep group
▼
| Cost category | Good sleepers | Symptoms | Syndrome | Ratio |
|---|---|---|---|---|
| Source values from Daley et al. (2009) Sleep 32(1), Table 2 — 1-year per person mean, CAD 2002. Converted to SGD at CAD→SGD 0.97 (mid-market); inflation to 2026 not applied — real burden today ~60–70% higher. | ||||
| Consultations (primary + secondary, incl. transport) | $22 | $31 | $171 | 7.8× |
| Medications (Rx + OTC) for insomnia | $0.12 | $4 | $21 | 175× |
| Alcohol as sleep aid | $22 | $121 | $92 | 4.2× |
| Absenteeism (insomnia-attributable) | $42 | $300 | $536 | 12.9× |
| Productivity loss (insomnia-attributable) | $323 | $933 | $4,039 | 12.5× |
| TOTAL combined (SGD, CAD 2002 × 0.97) | $409 | $1,388 | $4,860 | 11.9× |
Figures from Daley et al. (2009) Table 2 (1-year per person, CAD 2002), converted to SGD at CAD→SGD 0.97 (mid-market). SGD excess above good-sleeper baseline: ($4,860 − $409) = SGD $4,451 per syndrome employee; ($1,388 − $409) = SGD $980 per symptoms employee — these are the values used by the dashboard's ROI engine. 76% of all insomnia costs = productivity loss, not healthcare claims. Daley Quebec sample: n=493 good sleepers, 308 symptoms, 147 syndrome. Source: Daley, M., et al. (2009). Sleep, 32(1), 55–64.
Enterprise screening benchmark results (anonymized cohort, 118 employees)
▼
| Finding | Screened cohort | Projected at 3,000 |
|---|---|---|
| Moderate–severe insomnia (ISI 15+) | 12.7% | 381 employees |
| Subthreshold insomnia (ISI 8–14) | 51.7% | 1,551 employees |
| Any insomnia symptoms (ISI 8+) | 64.4% | 1,932 employees |
| Above-average sleep reactivity (FIRST > 23) | 35.6% | 1,068 employees |
| High-risk pool — FIRST > 23 OR ISI 8–14 (P3 union) | 67.8% | 2,034 employees |
| Moderate–high perceived stress (PSS 14+) | 81.3% | 2,439 employees |
| Measurable alertness lapses (PVT) | 28.8% | 864 employees |
| Sleep rated "Poor" or "Only Fair" | 51% | 1,530 employees |
| Relies on sleep medication / supplements | 16% | 480 employees |
| Discussed sleep with medical professional | 13% | 390 employees |
| Average weekday sleep duration | 7.2 hrs | -- |
| Average weekend sleep duration (social jetlag signal) | 8.5 hrs | -- |
| Average nightly sleep deficit vs desired (7.8 hrs) | 0.6 hrs | -- |
| Feels well-rested (days per week) | 2.7 days | -- |
| Daytime function impaired (days per week) | 2.3 days | -- |
| Moderate–high OSA risk (STOP-BANG) | 9.3% | 279 employees |
| Sleep-related movement disorder symptoms (GSAQ) | 7.6% | 228 employees |
| Parasomnia symptoms (GSAQ) | 0.8% | 24 employees |
| Shift-work sleep disorder | 2.5% | 75 employees |
Demographics:
- 85 Female / 33 Male
- Mean age 36.1 (SD 6.9)
- Mean SHI 76.9 (vs US 76)
- Source: Somnus Sleep Wellness enterprise screening benchmark, 2026 (anonymized aggregate cohort)
All findings are from self-administered clinical screeners validated in research literature.
RAND Europe 2023 — economic burden of insomnia (16-country OECD meta-study)
▼
| Measure | Figure | Source |
|---|---|---|
| Prevalence — any insomnia symptoms (ISI 8+) | 34% predicted | Meta-regression, 16 OECD countries (range 17.5–51.2%) |
| Prevalence — clinical insomnia (ISI 15+) | 14% predicted | Meta-regression (range 5.7–25.3%) |
| Prevalence — chronic insomnia (DSM-5) | 8% predicted | Meta-regression (range 6.0–14.8%) |
| Productivity days lost — insomnia symptoms | 23 days / year | ~14 absent + 30 presenteeism |
| Productivity days lost — chronic insomnia | 44–54 days / year | 11–18 absent + 39–45 presenteeism |
| Workplace injury risk with insomnia | +75–88% | Odds of accident leading to permanent work disability |
| Well-being cost (CIV) — % income traded | 14% | Willingness to trade income to eliminate insomnia (95% CI 8.3–20.1%) |
| Well-being cost — range across countries | $3,746–$7,675 / year | Per affected adult (Portugal to US, 2019 USD) |
| GDP loss from chronic insomnia — US | $207.5B / yr (1.06% GDP) | Macro-economic modelling, 2019 USD |
| GDP loss — UK | $41.4B / yr (1.31% GDP) | Highest % GDP impact in study |
| GDP loss — Australia | $19.2B / yr (1.24% GDP) | |
| GDP loss — Germany | $29.1B / yr (0.73% GDP) | |
| Working-age adults affected (16 countries) | 172m / 72m / 42m | Symptoms / clinical / chronic |
| Across 16 countries, chronic insomnia costs | $1.8–$207.5B / yr | Per country, from reduced productivity |
Source: Hafner, M., Romanelli, R. J., Yerushalmi, E., & Troxel, W. M. (2023). The societal and economic burden of insomnia in adults: An international study. RAND Europe, RR-A2166-1. 99pp. Funded by Idorsia Pharmaceuticals; independent editorial control retained by RAND. Report covers Australia, Austria, Belgium, Canada, Finland, France, Germany, Greece, Italy, Norway, Portugal, Spain, Sweden, Switzerland, UK and US.
Key sources
▼
| Source | Finding used in model |
|---|---|
| Daley et al. (2009) Sleep 32(1) | Per-person annual cost: syndrome CAD $5,010, symptoms $1,431, good sleepers $421. 76% of costs = productivity loss. |
| Kessler et al. (2011) Sleep 34(9) | Untreated insomnia = 11.3 lost performance days/yr, USD $2,280/employee/yr. |
| Fang et al. (2024) Sleep | CBT-I most cost-effective insomnia treatment. 60–80% improvement. Durable outcomes post-treatment. |
| Frost & Sullivan / AASM (2016) | Treating sleep apnea yields ~USD $3,000/employee/yr in productivity and healthcare savings. |
| Hafner et al. (2023) RAND Europe RR-A2166-1 | Chronic insomnia costs the US $207.5B/yr (1.06% GDP); 44–54 productivity days lost per year; 14% of household income traded to eliminate insomnia. 16-country OECD meta-study. |
Sources
- Daley et al. (2009) Sleep 32(1)
- Kessler et al. (2011) Sleep 34(9)
- Fang et al. (2024) Sleep
- Baglioni et al. (2016) Lancet Psychiatry
- Frost & Sullivan / AASM (2016)
- Somnus enterprise screening benchmark (anonymized cohort, 2026, N=118)
All figures in SGD. Conversions: CAD→SGD at 0.97, USD→SGD at 1.34. Daley costs in 2002 CAD; current burden likely higher. Figures directional; for planning purposes.